Vol 10, No 5 (2021)
Editorial
Published online: 2021-11-03

open access

Page views 5978
Article views/downloads 360
Get Citation

Connect on Social Media

Connect on Social Media

Gliptin Evidence to fight SARS-CoV-2 Infection

Francesco Ferrara1, Antonio Vitiello1
Clin Diabetol 2021;10(5):383-385.

Abstract

People with diabetes represent a population at greater risk of infection and complications from SARS-CoV-2. Diabetes represents one of the most important comorbidities related to the severity of viral infection causing an increased risk of serious complications such as severe acute respiratory syndrome and multi-organ dysfunction associated with a hyperinflammatory state. Glycemic normalization in patients with diabetes must be managed in the best possible way even during SARS-CoV-2 infection to avoid serious complications. However, for some antidiabetic agents such as DPP-4 inhibitors (gliptins) there is evidence of efficacy against SARS-CoV-2 extra pancreatic glycemic normalization. The objective of this article is to provide an overview of current evidence on the potential therapeutic benefits of gliptins to combat SARS-CoV-2 infection.

Article available in PDF format

View PDF Download PDF file

References

  1. World Health Organization HO (2020) Coronavirus disease 2019 (COVID-19) situation report. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.
  2. Vitiello A, Ferrara F, Pelliccia C, et al. Cytokine storm and colchicine potential role fighting SARS-CoV-2 pneumonia. Italian Journal of Medicine. 2020; 14(2): 88–94.
  3. Lin L, Lu L, Cao W, et al. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020; 9(1): 727–732.
  4. Ferrara F, Granata G, Pelliccia C, et al. The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2 : Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection? Eur J Clin Pharmacol. 2020; 76(11): 1615–1618.
  5. Vitiello A, Ferrara F. Correlation between renin-angiotensin system and Severe Acute Respiratory Syndrome Coronavirus 2 infection: What do we know? Eur J Pharmacol. 2020; 883: 173373.
  6. Zou Q, Zheng S, Wang X, et al. Influenza A-associated severe pneumonia in hospitalized patients: Risk factors and NAI treatments. Int J Infect Dis. 2020; 92: 208–213.
  7. Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? The Lancet. 2020; 395(10231): 1225–1228.
  8. Bornstein SR, Rubino F, Khunti K, et al. Practical recommendations for the management of diabetes in patients with COVID-19 Lancet Diabetes Endocrinol. Lancet Diabetes Endocrinol. 2020(8): 546–550.
  9. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181(2): 271–280.e8.
  10. Bindom SM, Lazartigues E. The sweeter side of ACE2: physiological evidence for a role in diabetes. Mol Cell Endocrinol. 2009; 302(2): 193–202.
  11. Yang JK, Lin SS, Ji XJ, et al. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010; 47(3): 193–199.
  12. Vitiello A, Ferrara F. Therapeutic Strategies for SARS-CoV-2 acting on ACE-2. Eur J Pharm Sci. 2021; 156: 105579.
  13. Vitiello A, Ferrara F. Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19. Life Sci. 2020; 262: 118510.
  14. Ferrara F. Anti-rheumatic in SARS-CoV-2: benefit or risk? Italian Journal of Medicine. 2020.
  15. Ferrara F, Porta RLa, D'Aiuto V, et al. Remdesivir and COVID-19. Ir J Med Sci. 2020 [Epub ahead of print].
  16. Vitiello A, Ferrara F, Porta RLa. Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks? Ir J Med Sci. 2021 [Epub ahead of print].
  17. Vitiello A, Ferrara F. Remdesivir versus ritonavir/lopinavir in COVID-19 patients. Ir J Med Sci. 2020 [Epub ahead of print].
  18. Ferrara F, Porta RLa, Santilli P, et al. Are multiple sclerosis therapies safe in severe acute respiratory syndrome coronavirus 2 times? Indian J Pharmacol. 2020; 52(5): 441–442.
  19. Raj V, Mou H, Smits S, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013; 495(7440): 251–254.
  20. Li K, Wohlford-Lenane CL, Channappanavar R, et al. Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice. Proc Natl Acad Sci U S A. 2017; 114(15): E3119–E3128.
  21. Fan C, Wu Xi, Liu Q, et al. A Human DPP4-Knockin Mouse's Susceptibility to Infection by Authentic and Pseudotyped MERS-CoV. Viruses. 2018; 10(9).
  22. Yang W, Cai X, Han X, et al. DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials. Diabetes Metab Res Rev. 2016; 32(4): 391–404.
  23. Raj V, Mou H, Smits S, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013; 495(7440): 251–254.
  24. Iacobellis G. COVID-19 and diabetes: Can DPP4 inhibition play a role? Diabetes Res Clin Pract. 2020; 162: 108125.
  25. Klonoff DC. The Coronavirus 2019 Pandemic and Diabetes: An International Perspective. J Diabetes Sci Technol. 2020; 14(4): 703–704.